# Design, Synthesis, and Molecular Docking of 1-(1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethylidene)-2-phenylhydrazine as Potent Nonazole Anticandidal Agent

Authors: Hazem A. Ghabbour; Maha M. Qabeel; Wagdy M. Eldehna; Abdullah Al-Dhfyan; Hatem A. Abdel-Aziz
Journal: Journal of Chemistry
 (2014)

---

## Abstract

1-(1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethylidene)-2-phenylhydrazine (13) was designed and synthesized as potential nonazole anticandidal agent and precisely characterized by IR, 1H NMR, 13C NMR, and ESI-MS. The anti-Candida activity of 13 was evaluated against four Candida species (C. albicans, C. krusei, C. parapsilosis, and C. glabrata). Compound 13 displayed good anticandidal activities (MIC=0.39, 0.195, 0.39, and 1.56 μmol/mL, resp.) in comparison with that of the standard drug fluconazole (MIC=0.195, inactive, 1.56, and 1.56 μmol/mL, resp.) against C. albicans, C. krusei, C. parapsilosis, and C. glabrata, respectively. A molecular modeling of the newly synthesized compound 13 was built in order to investigate its mode of action towards the prospective target cytochrome P450-dependent enzyme lanosterol 14α-demethylase (PDB-code: 1EA1). The docking results showed a similar binding interaction of 13 and fluconazole at the active site of CYT P450 14α-sterol demethylase. Furthermore, compound 13 showed no cytotoxicity against normal human breast cell line MCF10A.


---

## Body

## 1. Introduction

In the current medical era, human fungal infections have stood out as an important clinical threat, with serious associated morbidity and mortality [1]. The human immunodeficiency virus (HIV) epidemic, stem cell transplantation, and modern progression in the fields of solid organ transplantation coupled with the advent of novel immunosuppressive drugs have collectively resulted in dramatic increase in the incidence and diversity of human fungal infections including those caused byCandida,Aspergillus, andCryptococcus species [2].In the last few decades,Candida has emerged as one of the most prevalent fungal pathogens, causing both mucosal candidiasis and invasive candidemia, although it is a part of the microbiota of gastrointestinal and urogenital tracts, skin, and mouth in healthy individuals [3]. Many endogenous and exogenous predisposing factors such as immunological disorders, immoderate administration of antimicrobial agents, and prolonged use of invasive catheters may result in impaired host defence againstCandida spp. and, subsequently,Candida become pathogenic and disseminate into the bloodstream to infect different organs [4].According to the mode of action, there are main six classes of antifungal agents: fungal ergosterol synthesis inhibitors (azoles: ketoconazole, fluconazole, itraconazole, voriconazole, and posaconazole), ergosterol disruptors (polyenes antibiotics: amphotericin B and nystatin), squalene epoxidase inhibitors (terbinafine), glucan synthesis inhibitors (echinocandins, caspofungin, and micafungin), nucleic acid synthesis inhibitors (5-fluorocytosine), and chitin synthesis inhibitors (Nikkomycin and Polyoxins) [5–10].The azole antifungals are the mainstay of therapy usually used to treat differentCandida infections such as oropharyngeal and esophageal candidiasis, vulvovaginal candidiasis, candidemia, and disseminated candidiasis [11]. Azoles exert antifungal activity through inhibition of the fungal cytochrome P450-dependent 14α-lanosterol demethylase through the binding of the N3-atom of the azole moiety to the sixth coordination of heme iron atom of the porphyrin in the substrate binding site of the enzyme [12]. Due to the fungistatic action of azoles onCandida spp., cells repetitively exposed to these antifungals adapt to the drug pressure and eventually become azole resistant [13].On the other hand, azole antifungal agents showed fatal hepatotoxicity [14–16]. This side effect may be attributable to the imperfect specificity toward fungal enzyme where CYP51 is a member of the cytochrome P450 superfamily, which exists not only in fungi but in mammals [17, 18]. The limited success of azoles, due to severe resistance and fatal hepatotoxicity, has resulted in an urgent need to give much attention to update and modify drug leads from the point of view of medicinal chemistry and drug design to fulfill safe and more potent antifungals.Concerning the SAR of azoles antifungals, the azole ring has been evidenced to be one of the most important pharmacophores for the activity; also, it is a key toxicophore for the hepatotoxicity of azole antifungal drugs due to the coordination binding of its nitrogen atom to the iron atom of heme [19, 20]. All of these findings inspired us to design and prepare novel nonazole lead compound with different structural pharmacophores hoping to obtain potent antifungal agent and separate the antifungal activity from toxicity.Figure1 summarized the main structural features of a series of azoles antifungals such as imidazoles1–6 and triazole drugs7 and8 in addition to zinoconazole9 (Figure 1). In the present study, the well-known azole antifungals [21, 22] were chosen as lead compounds for development of new nonazole scaffold. Firstly, the heteroaryl rings were replaced with a phenyl ring. Since the anticandidal activity of hydrazones was extensively reported [23–25], we decided to retain the phenylhydrazine moiety of zinoconazole9.Figure 1
Structures of antifungal drugs1–9 and the title compound13.Finally, in the present work, utilization of sulfone group was performed depending on the reported antimicrobial activity of sulfones [26–28] and due to the incorporation of sulfur in some azole antifungals such as sulconazole4 and butoconazole5 in addition to the incorporation of oxygen in ether functions of econazole1, miconazole2, isoconazole3, and hydroxyl group of fluconazole7 and voriconazole8.In view of the facts mentioned above and as part of our ongoing effort to prepare biologically active agents [29–36], herein we present the design, synthesis, and preliminary biological evaluation of 1-(1-(4-chlorophenyl)-2-(phenylsulfonyl)ethylidene)-2-phenylhydrazine (13) as potent antifungal agent based on a novel nonazole scaffold. The mode of action of compound13 to the potential receptor cytochrome P450 14α-sterol demethylase was investigated by molecular docking.


## 2. Experimental

### 2.1. Chemistry

#### 2.1.1. General

Melting points were determined on a Gallenkamp melting point apparatus and are uncorrected. Infrared (IR) spectra were recorded as KBr disks using the Perkin Elmer FT-IR Spectrum BX apparatus. NMR spectra were scanned in DMSO-d6 on a Brucker NMR spectrometer operating at 500 MHz for 1H and 125 MHz for 13C. Chemical shifts are expressed in δ-values (ppm) relative to TMS as an internal standard. Coupling constants (J) are expressed in Hz. D2O was added to confirm the exchangeable protons. Mass spectra were measured on an Agilent Triple Quadrupole 6410 QQQ LC/MS equipped with an ESI (electrospray ionization) source.


#### 2.1.2. Synthesis of 1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethan-1-one (12)

This compound was prepared according to the reported method [37]. To a solution of 2-bromo-1-(4-chlorophenyl)ethan-1-one (10) (10 mmol) in absolute ethanol (50 mL), sodium benzenesulfinate (11) (12 mmol) was added. The mixture was refluxed for 3 h and then left to cool. The reaction mixture was poured into cold water and the solid product filtered off, washed with water, dried, and finally recrystallized from EtOH to afford compound12.


#### 2.1.3. Synthesis of 1-(1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethylidene)-2-phenylhydrazine (13)

A mixture of the sulfone12 (1 mmol) and phenyl hydrazine (1 mmol) in ethanol (30 mL) and acetic acid (0.5 mL) was added. The reaction mixture was stirred for 6 h. The precipitated product was filtered off, washed with ethanol, and dried. Recrystallization from ethanol to afford the corresponding hydrazone13 in 72%: m.p. 160–162°C; IR ν 3341 (NH) cm−1; 1H NMR (DSMO-d6) δ 5.17 (s, 2H, CH2), 6.82–6.85 (m, 1H, ArH), 7.12 (d, J=7.5 Hz, 2H, ArH), 7.23–7.26 (m, 2H, ArH), 7.32 (d, J=8 Hz, 2H, ArH), 7.53–7.56 (m, 2H, ArH), 7.59–7.63 (m, 1H, ArH), 7.71 (d, J=8.5 Hz, 2H, ArH), 9.81 (s, D2O exchangeable, 1H, NH); 13C NMR (DSMO-d6) δ 51.54, 113.00, 120.06, 127.26, 127.88, 128.12, 128.93, 128.97, 131.88, 133.93, 136.50, 139.26, 144.46; MS (ESI) m/z 384.7 [M]+.


#### 2.1.4. Synthesis of Compounds14a–d,15a,b, and16a,b

These compounds were synthesized recently in a previous study [29].


### 2.2. Antifungal Activity

In this study we used four reference strainsCandida albicans ATCC 90029,Candida parapsilosis ATCC 22019,Candida krusei ATCC 14247, andCandida glabrata ATCC 15126. Antifungal activity of the synthesized compounds was determined by the agar well diffusion method [38].A 1 × 106 CFUs/mL yeast suspension was prepared for each isolate in phosphate-buffered saline (PBS) and Mueller-Hinton agar plates were inoculated automatically with a Spiral plater (Autoplate 4000; Spiral Biotech, Inc., Bethesda, MD, USA). Subsequently, equidistant (1 cm diameter) holes were made using sterile cork borer in the agar. Holes were filled with 100 μL of the tested compound at concentration (100 μmol dissolved in 1 mL DMSO). 25 μg fluconazole and solvent were included as positive and negative controls, respectively. The plates were incubated for 24 h at 37°C. Afterwards, the antimicrobial activity of each newly synthesized compound was evaluated by measuring the inhibition zone diameters. The experiment was repeated on three separate occasions and the average zone of inhibition was calculated.


### 2.3. Minimal Inhibitory Concentration

The microdilution method was performed as described by Irobi et al. [39], with 96-well, round-bottom microtiter plates using RPMI 1640 medium (Life Technologies, New York, NY, USA) and 2% glucose in MOPS buffered to pH 7. Dimethyl sulphoxide (DMSO) was used as solvent for the synthetic compounds, starting with 100 μmol concentration of all compounds dissolved in 1 mL DMSO and then reduced by successive twofold dilutions of stock solution using a calibrated micropipette. The final solutions concentrations were 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, and 0.195 μmol/mL. The stock solutions of the synthetic compounds were dispersed in the assay medium to obtain appropriate concentrations in wells 1–10 in each row; drug-free medium was dispensed in wells 11 and 12. Fluconazole is used as reference drug. Sabouraud dextrose agar was used to culture yeast strains. The inoculums of microorganisms were prepared from cultures and were adjusted to 0.5 McFarland standard; the suspensions were further diluted in RPMI 1640 medium to yield an inoculum concentration of approximately 104 CFU/mL. The inoculated plates were incubated for 48 h at 35°C. Triplicate tests were performed and the average was taken as final reading. The MIC endpoint was defined as the lowest drug concentration exhibiting 100% inhibition of growth compared with the control well [40]. According to CLSI criteria 100% growth inhibition is defined as clear wells. Therefore, the readings at MIC value were similar to the negative control withoutCandida. The MIC of fluconazole was determined for each species in parallel as a control, and antibiotic-free solvent was included as a negative control.


### 2.4. Molecular Docking

The crystal structure of cytochrome P450 14α-sterol demethylase (Cyp51) fromMycobacterium tuberculosis in complex with fluconazole (PDB 1EA1) was provided from Brookhaven protein data bank (PDB; http://www.rcsb.org/pdb) and loaded to Molegro Virtual Docker (MVD 2013.6.0.0 [win32]) program, fully functional free trial version with time limiting license [41] The nonbonded oxygen atoms of water, present in the crystal structure, was removed. ChemBio3D Ultra 10 [42] was used to draw the 3D structures of different ligands. Ligands were further preoptimized using free version of Marvinsketch 4.1.13 from Chemaxon Ltd [43] with MM force field and saved in Tripos mol2 file format. MolDock score functions were used with a 0.3 Å grid resolution. The binding sites were defined to any residues with 10 Å distant from the cocrystallized fluconazole in the complex crystal structure of the enzyme [44].


### 2.5. Apoptotic Evaluation for Compound13

Apoptotic effect of compound13 against noncancerous human breast epithelial cell line MCF10A by measurement of annexin-V binding by flow cytometry was performed according to the reported method with minor modification [45].


## 2.1. Chemistry

### 2.1.1. General

Melting points were determined on a Gallenkamp melting point apparatus and are uncorrected. Infrared (IR) spectra were recorded as KBr disks using the Perkin Elmer FT-IR Spectrum BX apparatus. NMR spectra were scanned in DMSO-d6 on a Brucker NMR spectrometer operating at 500 MHz for 1H and 125 MHz for 13C. Chemical shifts are expressed in δ-values (ppm) relative to TMS as an internal standard. Coupling constants (J) are expressed in Hz. D2O was added to confirm the exchangeable protons. Mass spectra were measured on an Agilent Triple Quadrupole 6410 QQQ LC/MS equipped with an ESI (electrospray ionization) source.


### 2.1.2. Synthesis of 1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethan-1-one (12)

This compound was prepared according to the reported method [37]. To a solution of 2-bromo-1-(4-chlorophenyl)ethan-1-one (10) (10 mmol) in absolute ethanol (50 mL), sodium benzenesulfinate (11) (12 mmol) was added. The mixture was refluxed for 3 h and then left to cool. The reaction mixture was poured into cold water and the solid product filtered off, washed with water, dried, and finally recrystallized from EtOH to afford compound12.


### 2.1.3. Synthesis of 1-(1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethylidene)-2-phenylhydrazine (13)

A mixture of the sulfone12 (1 mmol) and phenyl hydrazine (1 mmol) in ethanol (30 mL) and acetic acid (0.5 mL) was added. The reaction mixture was stirred for 6 h. The precipitated product was filtered off, washed with ethanol, and dried. Recrystallization from ethanol to afford the corresponding hydrazone13 in 72%: m.p. 160–162°C; IR ν 3341 (NH) cm−1; 1H NMR (DSMO-d6) δ 5.17 (s, 2H, CH2), 6.82–6.85 (m, 1H, ArH), 7.12 (d, J=7.5 Hz, 2H, ArH), 7.23–7.26 (m, 2H, ArH), 7.32 (d, J=8 Hz, 2H, ArH), 7.53–7.56 (m, 2H, ArH), 7.59–7.63 (m, 1H, ArH), 7.71 (d, J=8.5 Hz, 2H, ArH), 9.81 (s, D2O exchangeable, 1H, NH); 13C NMR (DSMO-d6) δ 51.54, 113.00, 120.06, 127.26, 127.88, 128.12, 128.93, 128.97, 131.88, 133.93, 136.50, 139.26, 144.46; MS (ESI) m/z 384.7 [M]+.


### 2.1.4. Synthesis of Compounds14a–d,15a,b, and16a,b

These compounds were synthesized recently in a previous study [29].


## 2.1.1. General

Melting points were determined on a Gallenkamp melting point apparatus and are uncorrected. Infrared (IR) spectra were recorded as KBr disks using the Perkin Elmer FT-IR Spectrum BX apparatus. NMR spectra were scanned in DMSO-d6 on a Brucker NMR spectrometer operating at 500 MHz for 1H and 125 MHz for 13C. Chemical shifts are expressed in δ-values (ppm) relative to TMS as an internal standard. Coupling constants (J) are expressed in Hz. D2O was added to confirm the exchangeable protons. Mass spectra were measured on an Agilent Triple Quadrupole 6410 QQQ LC/MS equipped with an ESI (electrospray ionization) source.


## 2.1.2. Synthesis of 1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethan-1-one (12)

This compound was prepared according to the reported method [37]. To a solution of 2-bromo-1-(4-chlorophenyl)ethan-1-one (10) (10 mmol) in absolute ethanol (50 mL), sodium benzenesulfinate (11) (12 mmol) was added. The mixture was refluxed for 3 h and then left to cool. The reaction mixture was poured into cold water and the solid product filtered off, washed with water, dried, and finally recrystallized from EtOH to afford compound12.


## 2.1.3. Synthesis of 1-(1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethylidene)-2-phenylhydrazine (13)

A mixture of the sulfone12 (1 mmol) and phenyl hydrazine (1 mmol) in ethanol (30 mL) and acetic acid (0.5 mL) was added. The reaction mixture was stirred for 6 h. The precipitated product was filtered off, washed with ethanol, and dried. Recrystallization from ethanol to afford the corresponding hydrazone13 in 72%: m.p. 160–162°C; IR ν 3341 (NH) cm−1; 1H NMR (DSMO-d6) δ 5.17 (s, 2H, CH2), 6.82–6.85 (m, 1H, ArH), 7.12 (d, J=7.5 Hz, 2H, ArH), 7.23–7.26 (m, 2H, ArH), 7.32 (d, J=8 Hz, 2H, ArH), 7.53–7.56 (m, 2H, ArH), 7.59–7.63 (m, 1H, ArH), 7.71 (d, J=8.5 Hz, 2H, ArH), 9.81 (s, D2O exchangeable, 1H, NH); 13C NMR (DSMO-d6) δ 51.54, 113.00, 120.06, 127.26, 127.88, 128.12, 128.93, 128.97, 131.88, 133.93, 136.50, 139.26, 144.46; MS (ESI) m/z 384.7 [M]+.


## 2.1.4. Synthesis of Compounds14a–d,15a,b, and16a,b

These compounds were synthesized recently in a previous study [29].


## 2.2. Antifungal Activity

In this study we used four reference strainsCandida albicans ATCC 90029,Candida parapsilosis ATCC 22019,Candida krusei ATCC 14247, andCandida glabrata ATCC 15126. Antifungal activity of the synthesized compounds was determined by the agar well diffusion method [38].A 1 × 106 CFUs/mL yeast suspension was prepared for each isolate in phosphate-buffered saline (PBS) and Mueller-Hinton agar plates were inoculated automatically with a Spiral plater (Autoplate 4000; Spiral Biotech, Inc., Bethesda, MD, USA). Subsequently, equidistant (1 cm diameter) holes were made using sterile cork borer in the agar. Holes were filled with 100 μL of the tested compound at concentration (100 μmol dissolved in 1 mL DMSO). 25 μg fluconazole and solvent were included as positive and negative controls, respectively. The plates were incubated for 24 h at 37°C. Afterwards, the antimicrobial activity of each newly synthesized compound was evaluated by measuring the inhibition zone diameters. The experiment was repeated on three separate occasions and the average zone of inhibition was calculated.


## 2.3. Minimal Inhibitory Concentration

The microdilution method was performed as described by Irobi et al. [39], with 96-well, round-bottom microtiter plates using RPMI 1640 medium (Life Technologies, New York, NY, USA) and 2% glucose in MOPS buffered to pH 7. Dimethyl sulphoxide (DMSO) was used as solvent for the synthetic compounds, starting with 100 μmol concentration of all compounds dissolved in 1 mL DMSO and then reduced by successive twofold dilutions of stock solution using a calibrated micropipette. The final solutions concentrations were 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, and 0.195 μmol/mL. The stock solutions of the synthetic compounds were dispersed in the assay medium to obtain appropriate concentrations in wells 1–10 in each row; drug-free medium was dispensed in wells 11 and 12. Fluconazole is used as reference drug. Sabouraud dextrose agar was used to culture yeast strains. The inoculums of microorganisms were prepared from cultures and were adjusted to 0.5 McFarland standard; the suspensions were further diluted in RPMI 1640 medium to yield an inoculum concentration of approximately 104 CFU/mL. The inoculated plates were incubated for 48 h at 35°C. Triplicate tests were performed and the average was taken as final reading. The MIC endpoint was defined as the lowest drug concentration exhibiting 100% inhibition of growth compared with the control well [40]. According to CLSI criteria 100% growth inhibition is defined as clear wells. Therefore, the readings at MIC value were similar to the negative control withoutCandida. The MIC of fluconazole was determined for each species in parallel as a control, and antibiotic-free solvent was included as a negative control.


## 2.4. Molecular Docking

The crystal structure of cytochrome P450 14α-sterol demethylase (Cyp51) fromMycobacterium tuberculosis in complex with fluconazole (PDB 1EA1) was provided from Brookhaven protein data bank (PDB; http://www.rcsb.org/pdb) and loaded to Molegro Virtual Docker (MVD 2013.6.0.0 [win32]) program, fully functional free trial version with time limiting license [41] The nonbonded oxygen atoms of water, present in the crystal structure, was removed. ChemBio3D Ultra 10 [42] was used to draw the 3D structures of different ligands. Ligands were further preoptimized using free version of Marvinsketch 4.1.13 from Chemaxon Ltd [43] with MM force field and saved in Tripos mol2 file format. MolDock score functions were used with a 0.3 Å grid resolution. The binding sites were defined to any residues with 10 Å distant from the cocrystallized fluconazole in the complex crystal structure of the enzyme [44].


## 2.5. Apoptotic Evaluation for Compound13

Apoptotic effect of compound13 against noncancerous human breast epithelial cell line MCF10A by measurement of annexin-V binding by flow cytometry was performed according to the reported method with minor modification [45].


## 3. Results and Discussion

### 3.1. Chemistry

1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethan-1-one (12) was synthesized by the reaction of 2-bromo-1-(4-chlorophenyl)ethan-1-one (10) with sodium benzenesulfinate (11) (Scheme 1) [37]. Sulfone12 was reacted with phenylhydrazine in ethanol at ambient temperature to afford the title compound13 (Scheme 1). The IR spectrum of compound13 revealed the appearance of absorption band of hydrazone NH at 3341 cm−1. The 1H NMR of hydrazone13 exhibited the signal of the NH group which appeared at δ 9.81 and the signal of CH2 protons appeared as singlet at δ 5.17 whereas its 13C NMR revealed the signal of CH2 carbon at δ 51.54. The MS (ESI) analysis of13 showed a peak at m/z=384.7 [M]+.Scheme 1
Synthetic pathway of the title compound13.In a previous study published recently, we synthesized compounds14a–d,15a,b, and16a,b (Scheme 2) investigated here [29].Scheme 2
Structure of compounds14a–d,15a,b, and16a,b [29].


### 3.2. Antifungal Activity

Compounds14a–d,15a,b, and16a,b [29] and the newly synthesized compound13 were evaluatedin vitro for their antifungal activity, by inhibition zone technique, using fourCandida species (C. albicans,C. krusei,C. parapsilosis, andC. glabrata). The mean values of the inhibition zone diameter obtained for compound13 suggest that compound13 possesses significant antifungal activity againstC. albicans,C. krusei, andC. parapsilosis (Table 1).Table 1
Antifungal activity of compounds13–16 in mean inhibition diameters (mm).
Compounds
C. albicans
C. krusei
C. parapsilosis
C. glabrata
13
33
39
35
22
14a
—
—
—
—
14b
—
—
—
—
14c
14
11
18
12
14d
—
—
—
—
15a
—
—
—
—
15b
—
—
—
—
16a
—
—
—
—
16b
—
—
—
—
Fluconazole
29
—
27
23


### 3.3. Minimum Inhibitory Concentration (MIC)

Thereafter, minimum inhibitory concentration (MIC) of the compound13 is evaluatedin vitro using the twofold serial dilution technique. The lowest concentration showing no growth was chosen as the MIC. The results of minimum inhibitory concentration were displayed in Table 2.Table 2
Minimum inhibitory concentration (MIC) inμmol/mL of 13.
Compound
C. albicans
C. krusei
C. parapsilosis
C. glabrata
13
0.39
0.195
0.39
1.56
Fluconazole
0.195
—
1.56
1.56The antifungal activity of13 was compared with that of fluconazole, a standard antifungal drug. Investigations of the antifungal activity againstC. krusei andC. parapsilosis indicated that they were the most sensitive species to the influence of the compound13 with MIC values of 0.195 and 0.39 μmol/mL, respectively. Also, compound13 almost was equipotent as fluconazole againstC. glabrata (MIC = 1.56 μmol/mL). On the other hand, compound13 was 2-fold less active than fluconazole againstC. albicans with MIC value of 0.39 μmol/mL.


### 3.4. Structure Activity Relationship for Compound13

From the SAR point of view, theN-phenyl ring and hydrazone function of13 is necessary for its activity. The activity of compound13 may be due to the presence of three electron clouds of aryl groups with similar distribution with those of fluconazole (two triazole moieties and benzene ring).


### 3.5. Molecular Docking Study for Compound13

Docking study was performed for13 in order to investigate the possible interactions with cytochrome P450 14α-sterol demethylase fromMycobacterium tuberculosis (Mycobacterium P450 DM). The crystallographic structure of the complex between cytochrome P450 14α-sterol demethylase fromMycobacterium tuberculosis (Mycobacterium P450 DM) and fluconazole (ID 1EA1) was used for the docking study [46].Figure2(a) shows the docked reference drug fluconazole in the active site of the enzyme for validation of our docking protocol. Azole ring is positioned almost perpendicular to the porphyrin plane (cofactor) where the nitrogen of azole ring coordinated to the heme iron. The distance between nitrogen atom of azole ring in fluconazole and heme ring was 2.34 Å. Fluconazole revealed a MolDock score of −161.29. In case of compound13, the oxygen of sulfone moiety is perpendicular to the porphyrin plane heme ion with distance 3.44 Å (Figure 2(b)). The phenyl ring of13 occupied the hydrophobic region above the heme ring and showed good van der Waals interactions with heme and amino acids Tyr76, Phe78, Phe83, and Phe255. Compound13 showed excellent MolDock score −165.87 better than that of fluconazole (−161.29) consistent with the results of antifungal activity of13 and fluconazole.(a) Binding mode of fluconazole into the binding site cytochrome P450 14α-sterol demethylase. (b) Binding mode of13 into the binding site cytochrome P450 14α-sterol demethylase.
(a)
(b)It was observed that compound13 was oriented in the binding groove of enzyme in such fashion that favors the possibility of  π–π  interaction of its three benzene rings with the hydrophobic amino acid residues of the binding site of the enzyme (Figure 3). The latter binding interactions of13 are the same as that of fluconazole with binding site of the enzyme (Figure 3). In addition, the sulfone moiety in13 occupies the same position of the hydroxyl group in fluconazole as shown in Figure 3.Figure 3
Overlay of compound13 (blue) and fluconazole (red) showing their 3D and 2D binding interactions in the groove of cytochrome P450 14α-sterol demethylase.


### 3.6. Apoptotic Activity Evaluation for Compound13

It has been shown that loss of phospholipid asymmetry of the plasma membrane is an early event of apoptosis. The annexin-V binds to negatively charged phospholipids, like phosphatidylserine. During apoptosis, the cells react to annexin-V once chromatin condenses but before the plasma membrane loses its ability to exclude DAPI. Hence, by staining cells with a combination of APC annexin-V and DAPI it is possible to detect nonapoptotic live cells, early apoptotic cells, and late apoptotic or necrotic cells. Apoptotic effect of compound13 against noncancerous human breast epithelial cell line MCF10A showed no effect between the treated (10 μM) and the untreated cells (Figure 4).Figure 4
Measurement of annexin-V binding by flow cytometry. Apoptotic effects of compound13 against noncancerous human breast epithelial cell line MCF10A showed no effect between the treated (10 μM) and the untreated cells.


## 3.1. Chemistry

1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethan-1-one (12) was synthesized by the reaction of 2-bromo-1-(4-chlorophenyl)ethan-1-one (10) with sodium benzenesulfinate (11) (Scheme 1) [37]. Sulfone12 was reacted with phenylhydrazine in ethanol at ambient temperature to afford the title compound13 (Scheme 1). The IR spectrum of compound13 revealed the appearance of absorption band of hydrazone NH at 3341 cm−1. The 1H NMR of hydrazone13 exhibited the signal of the NH group which appeared at δ 9.81 and the signal of CH2 protons appeared as singlet at δ 5.17 whereas its 13C NMR revealed the signal of CH2 carbon at δ 51.54. The MS (ESI) analysis of13 showed a peak at m/z=384.7 [M]+.Scheme 1
Synthetic pathway of the title compound13.In a previous study published recently, we synthesized compounds14a–d,15a,b, and16a,b (Scheme 2) investigated here [29].Scheme 2
Structure of compounds14a–d,15a,b, and16a,b [29].


## 3.2. Antifungal Activity

Compounds14a–d,15a,b, and16a,b [29] and the newly synthesized compound13 were evaluatedin vitro for their antifungal activity, by inhibition zone technique, using fourCandida species (C. albicans,C. krusei,C. parapsilosis, andC. glabrata). The mean values of the inhibition zone diameter obtained for compound13 suggest that compound13 possesses significant antifungal activity againstC. albicans,C. krusei, andC. parapsilosis (Table 1).Table 1
Antifungal activity of compounds13–16 in mean inhibition diameters (mm).
Compounds
C. albicans
C. krusei
C. parapsilosis
C. glabrata
13
33
39
35
22
14a
—
—
—
—
14b
—
—
—
—
14c
14
11
18
12
14d
—
—
—
—
15a
—
—
—
—
15b
—
—
—
—
16a
—
—
—
—
16b
—
—
—
—
Fluconazole
29
—
27
23


## 3.3. Minimum Inhibitory Concentration (MIC)

Thereafter, minimum inhibitory concentration (MIC) of the compound13 is evaluatedin vitro using the twofold serial dilution technique. The lowest concentration showing no growth was chosen as the MIC. The results of minimum inhibitory concentration were displayed in Table 2.Table 2
Minimum inhibitory concentration (MIC) inμmol/mL of 13.
Compound
C. albicans
C. krusei
C. parapsilosis
C. glabrata
13
0.39
0.195
0.39
1.56
Fluconazole
0.195
—
1.56
1.56The antifungal activity of13 was compared with that of fluconazole, a standard antifungal drug. Investigations of the antifungal activity againstC. krusei andC. parapsilosis indicated that they were the most sensitive species to the influence of the compound13 with MIC values of 0.195 and 0.39 μmol/mL, respectively. Also, compound13 almost was equipotent as fluconazole againstC. glabrata (MIC = 1.56 μmol/mL). On the other hand, compound13 was 2-fold less active than fluconazole againstC. albicans with MIC value of 0.39 μmol/mL.


## 3.4. Structure Activity Relationship for Compound13

From the SAR point of view, theN-phenyl ring and hydrazone function of13 is necessary for its activity. The activity of compound13 may be due to the presence of three electron clouds of aryl groups with similar distribution with those of fluconazole (two triazole moieties and benzene ring).


## 3.5. Molecular Docking Study for Compound13

Docking study was performed for13 in order to investigate the possible interactions with cytochrome P450 14α-sterol demethylase fromMycobacterium tuberculosis (Mycobacterium P450 DM). The crystallographic structure of the complex between cytochrome P450 14α-sterol demethylase fromMycobacterium tuberculosis (Mycobacterium P450 DM) and fluconazole (ID 1EA1) was used for the docking study [46].Figure2(a) shows the docked reference drug fluconazole in the active site of the enzyme for validation of our docking protocol. Azole ring is positioned almost perpendicular to the porphyrin plane (cofactor) where the nitrogen of azole ring coordinated to the heme iron. The distance between nitrogen atom of azole ring in fluconazole and heme ring was 2.34 Å. Fluconazole revealed a MolDock score of −161.29. In case of compound13, the oxygen of sulfone moiety is perpendicular to the porphyrin plane heme ion with distance 3.44 Å (Figure 2(b)). The phenyl ring of13 occupied the hydrophobic region above the heme ring and showed good van der Waals interactions with heme and amino acids Tyr76, Phe78, Phe83, and Phe255. Compound13 showed excellent MolDock score −165.87 better than that of fluconazole (−161.29) consistent with the results of antifungal activity of13 and fluconazole.(a) Binding mode of fluconazole into the binding site cytochrome P450 14α-sterol demethylase. (b) Binding mode of13 into the binding site cytochrome P450 14α-sterol demethylase.
(a)
(b)It was observed that compound13 was oriented in the binding groove of enzyme in such fashion that favors the possibility of  π–π  interaction of its three benzene rings with the hydrophobic amino acid residues of the binding site of the enzyme (Figure 3). The latter binding interactions of13 are the same as that of fluconazole with binding site of the enzyme (Figure 3). In addition, the sulfone moiety in13 occupies the same position of the hydroxyl group in fluconazole as shown in Figure 3.Figure 3
Overlay of compound13 (blue) and fluconazole (red) showing their 3D and 2D binding interactions in the groove of cytochrome P450 14α-sterol demethylase.


## 3.6. Apoptotic Activity Evaluation for Compound13

It has been shown that loss of phospholipid asymmetry of the plasma membrane is an early event of apoptosis. The annexin-V binds to negatively charged phospholipids, like phosphatidylserine. During apoptosis, the cells react to annexin-V once chromatin condenses but before the plasma membrane loses its ability to exclude DAPI. Hence, by staining cells with a combination of APC annexin-V and DAPI it is possible to detect nonapoptotic live cells, early apoptotic cells, and late apoptotic or necrotic cells. Apoptotic effect of compound13 against noncancerous human breast epithelial cell line MCF10A showed no effect between the treated (10 μM) and the untreated cells (Figure 4).Figure 4
Measurement of annexin-V binding by flow cytometry. Apoptotic effects of compound13 against noncancerous human breast epithelial cell line MCF10A showed no effect between the treated (10 μM) and the untreated cells.


## 4. Conclusion

In conclusion, 1-(1-(4-chlorophenyl)-2-(phenylsulfonyl)ethylidene)-2-phenylhydrazine (13) was prepared by the reaction of β-ketosulfone12 with phenyl hydrazine and its structure was established under the basis of its spectral data. It showed excellent antifungal activities againstCandida fungal species. The molecular modeling results showed a similar binding interaction of13 and fluconazole in the active site of CYTP-450. The phenylhydrazone moiety plays an important role in the antifungal potentiality of13. In addition, compound13 showed no cytotoxicity against noncancerous cell line MCF10A.



---

*Source: 154357-2014-12-31.xml*